Fangsheng Pharmaceutical(SH:603998) Xin Lang Zheng Quan·2025-09-23 02:50Core Viewpoint - Fangsheng Pharmaceutical's stock price has shown fluctuations, with a year-to-date increase of 12.39% and a recent decline over the past 20 days, indicating mixed market sentiment [2]. Company Overview - Fangsheng Pharmaceutical, established on October 13, 1997, and listed on December 5, 2014, is located in Changsha, Hunan Province. The company specializes in the research, production, and sales of traditional Chinese medicine for cardiovascular, orthopedic, pediatric, and anti-infection treatments [2]. - The company's revenue composition is primarily from product sales (94.62%) and service provision (5.38%) [2]. - As of June 30, 2025, the company had 33,100 shareholders, a slight increase of 0.37% from the previous period, with an average of 13,245 circulating shares per shareholder, down by 0.36% [2]. Financial Performance - For the first half of 2025, Fangsheng Pharmaceutical reported a revenue of 834 million yuan, a year-on-year decrease of 8.35%. However, the net profit attributable to shareholders increased by 23.67% to 169 million yuan [2]. - The company has distributed a total of 689 million yuan in dividends since its A-share listing, with 484 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the top three circulating shareholders include ICBC Medical Health Stock (000831) with 5.40 million shares, unchanged from the previous period, and Rongtong Health Industry Flexible Allocation Mixed A/B (000727) with 5.00 million shares, which increased by 500,000 shares [3]. - Notably, E Fund Healthcare Industry Mixed A (110023) and Anxin Pharmaceutical Health Stock A (010709) have exited the top ten circulating shareholders list [3].